Zolgensma, a one-off treatment for infants born with a rare and often fatal genetic disease, came to the market five years ago at an... Read this story
Zolgensma, a one-off treatment for infants born with a rare and often fatal genetic disease, came to the market five years ago at an... Read this story
More from SWI swissinfo.ch | Article Business Health healthcare policy Human interest medicine beat-Multinational companies Multinationals pharmaceutical prices Pharmaceutical industry Medicine Novartis Spinal muscular atrophy